[Immunobiological properties and therapeutic effectiveness of preparations from Klebsiella bacteriophages]
Related Experiment Video
Updated: Oct 2, 2026

Bacteriophage Effectiveness for Biocontrol of Foodborne Pathogens Evaluated via High-Throughput Settings
Published on: August 19, 2021
Abstract:
The purified preparations of Klebsiella bacteriophages, viz. the monovalent preparation of K. pneumoniae bacteriophage and the polyvalent bacteriophage preparation for the treatment of infections caused by K. ozaenae, K. rhinoscleromatis scleromatis and K. pneumoniae sensu lato, have been obtained. The bacteriophage preparations have proved to be nontoxic and safe for laboratory animals after the intraperitoneal injection of these preparations followed by the pathomorphological study of the internal organs of the animals. The clinical study of the newly developed bacteriophage preparations in the course of the treatment of purulent inflammatory diseases in 109 patients has revealed that the preparations are not reactogenic and exhibit sufficient effectiveness in the therapy of ozena, rhinoscleroma and Klebsiella infections with different localization of the infectious process.
Insights
New Klebsiella bacteriophage preparations are safe and effective for treating infections like ozena and rhinoscleroma. Clinical studies show these non-toxic bacteriophages offer a viable therapeutic option for various Klebsiella-related conditions.
Area of Science:
- Microbiology
- Virology
- Immunology
Context:
- Klebsiella species are significant human pathogens.
- Bacteriophage therapy offers an alternative to antibiotics.
- Development of targeted antimicrobial agents is crucial.
Purpose:
- To obtain purified Klebsiella bacteriophage preparations.
- To evaluate the safety and efficacy of these bacteriophage preparations.
- To assess their therapeutic potential in treating Klebsiella infections.
Summary:
- Monovalent and polyvalent Klebsiella bacteriophage preparations were successfully obtained.
- Pre-clinical studies confirmed the non-toxic and safe profile in laboratory animals.
- Clinical trials in 109 patients demonstrated safety, non-reactogenicity, and effectiveness against ozena, rhinoscleroma, and other Klebsiella infections.
Impact:
- Provides novel, safe, and effective bacteriophage-based therapeutics for Klebsiella infections.
- Offers a promising alternative or adjunct to antibiotic therapy.
- Contributes to the management of challenging infectious diseases caused by Klebsiella species.
Related Concept Videos
Lytic Cycle of Bacteriophages
Microorganisms in Medicine and Therapeutics
Biological Methods for Microbial Control
DNA Bacteriophages
Bacteriophages of the Human Virome
Regulation of Bacterial Virulence

